Phase 2 Crohn's Disease and Colitis Trial, Recruiting NCT05287126 Sponsor: Pfizer Condition: Crohn's Disease and Colitis
Back to Crohns Disease And Colitis

Phase 2 Crohn's Disease and Colitis Trial, Recruiting

NCT05287126
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with moderately to severely active ulcerative colitis (a condition causing inflammation of the large intestine)
  • People who are currently taking certain approved medications for ulcerative colitis at a therapeutic dose may still be considered

Who may not be able to join:

  • People with a very severe form of ulcerative colitis that affects a large portion of the colon
  • People who have been diagnosed with Crohn's disease or indeterminate colitis (a type of bowel inflammation that is difficult to classify), or who have or have had a fistula (an abnormal tunnel-like connection in the body) that may suggest Crohn's disease
  • People who have been diagnosed with microscopic colitis, ischemic colitis (reduced blood flow to the colon), or colitis caused by an infection

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Pfizer CT.gov Call Center, Pfizer

Phone: 1-800-718-1021

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Registry
ClinicalTrials.gov
Start date
16 December 2022
Est. completion
16 June 2029

Where this trial is recruiting

🇯🇵 Japan 🇵🇱 Poland 🇸🇰 Slovakia 🇪🇸 Spain 🇺🇸 United States

Primary endpoints

Proportion of Participants Achieving Clinical Remission as Assessed by Modified Mayo Score (MMS) at Week 52

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov